1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Genetic Technologies Limited

Genetic Technologies Limited

GNTLF
Genetic Technologies LimitedUS flagOther OTC
1.00
USD
- -
- -
1.34BMarket Cap
Genetic Technologies Limited
GNTLF
(Other OTC)

Recent

price

1.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
2.85
1.2
1.06
0.75
0.67
0.71
0.18
0.04
0.02
0.01
- -
- -
- -
0.07
0.09
0.06
- -
Revenue per Share
-1.96
-2.29
0.21
-1.07
-1.84
-1.57
-0.77
-0.46
-0.37
-0.22
-0.24
-0.15
-0.08
-0.08
-0.12
-0.09
- -
Basic EPS, GAAP
-1.28
-1.38
0.48
-0.02
-1.5
-1.71
-0.86
-0.44
-0.01
-0.23
- -
- -
-0.01
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3.06
0.98
1.13
2.13
0.33
-0.33
1.24
0.32
0.2
-0.04
-0.16
0.1
0.12
0.05
0.05
-0.02
- -
Book Value per Share
2.38
0.96
1.18
2.63
0.88
0.1
1.59
0.61
0.47
0.19
0.07
0.34
0.25
0.12
0.07
- -
- -
Tangible Book Value per Share
4
4
4
5
5
6
11
18
23
24
26
42
85
92
101
132
- -
Basic Weighted Avg Shares
11
5
5
4
3
5
2
1
1
- -
- -
- -
- -
7
9
8
- -
Sales/Revenue/Turnover
-72.3
-206
22.8
-298.55
-276.16
-215.88
-484.88
-1,038.38
-1,527.1
-3,316.52
-27,581.59
-44,506.85
-6,802.95
-134.02
-130.91
-159.3
- -
Operating Margin (%)
4
4
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
Depreciation Expense
-8
-9
1
-5
-9
-10
-9
-8
-8
-5
-6
-6
-7
-7
-12
-12
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-68.82
-190.09
19.8
-143.25
-275.33
-221.84
-437.9
-1,025.84
-1,620.78
-2,887.06
-25,253.91
-63,815.64
-5,870.91
-104.95
-135.28
-156.78
- -
Profit Margin (%)
6
2
4
8
- -
2
18
11
10
5
2
14
21
11
7
-1
- -
Working Capital
- -
- -
- -
- -
- -
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
14
6
7
14
6
2
19
12
11
5
2
14
22
16
11
2
- -
Total Equity
- -
- -
16.21
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
20.51
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-47.67
-114.93
20.41
-68.48
-152.25
- -
- -
-84.21
-162.19
- -
- -
- -
-97.19
-92.42
-245.85
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'25
ST Debt
- -
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
101
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'25
Total Current Assets
- -
4
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
4
- -
Payables & Accruals
- -
2
- -
ST Debt
- -
1
- -
Deferred Revenue
- -
1
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
137.58%
120.91%
-83.6%
Free Cash Flow
382.94%
351.94%
87.82%
Net Income, GAAP
4.32%
15.64%
2.27%
Sales/Revenue/Turnover
631.12%
1,322.67%
-11.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
9
2024
- -
- -
- -
- -
8
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.12
2024
- -
- -
- -
- -
-0.09
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Sofiva Genomics Co.,Ltd. (6615.TWO)
Invitae Corporation (NVTAQ)
Clearbridge Health Limited (1H3.SI)
Hypha Labs, Inc. (FUNI)
Integrative Health Technologies, Inc. (IHTI)
Taihe Group, Inc. (TIHE)
Business
Genetic Technologies Limited (GTG.AX; GNTLF), an Australia-based molecular diagnostics company founded in 1987 and headquartered in Fitzroy, Australia, develops and commercializes predictive genetic testing and risk assessment tools primarily focused on women's health and chronic disease prevention; core offerings include the flagship BREVAGenplus, a clinically validated multi-gene panel test for non-hereditary breast and ovarian cancer risk marketed to breast imaging centers, obstetricians/gynecologists, and oncology specialists; GeneType portfolio tests for colorectal cancer, prostate cancer, melanoma, type 2 diabetes, coronary artery disease, pancreatic cancer, and atrial fibrillation; EasyDNA consumer genetic testing services encompassing paternity, relationship, ancestry, health predispositions, animal, forensic, and plant testing; and AffinityDNA direct-to-consumer kits for similar categories; the company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments, serving physicians, healthcare professionals, and consumers across Australia, the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific with research collaborations including the University of Melbourne and Translational Genomics Research Institute. In June 2025, Genetic Technologies signed a letter of intent to acquire Ellerfield Wealth Pty Ltd for AUD 7 million to expand into wealth management services; the company rebranded its primary platform to geneType.com with a modernized geneType risk assessment offering featuring simple buccal/saliva collection, clinically actionable results, complimentary genetic counseling access, and privacy-focused single-purpose data usage targeting medical practitioners for personalized health management.